Hans joined Synerkine Pharma mid 2018 as CEO and is one of the founders. He also runs a private consultancy business since January 2016. He supports some Dutch and international biotech companies with their business development activities as well as with their challenges in process development and GMP manufacturing. He is also member of the supervisory board of DCprime (Leiden, the Netherlands).
Prior to starting his own consultancy, Hans worked for several biotech and pharma companies in the Netherlands such Solvay Pharmaceuticals (now Abbott), DSM Biologics and Gist-brocades (now DSM) and uniQure. At uniQure he was initially responsible for process development and GMP manufacturing of their gene therapy vectors and led projects from early phases up to the regulatory approval of the first approved gene therapy product in the world (outside China). Later, he became uniQure’s Chief Business Officer.
Hans Preusting holds a PhD in Biochemistry from the university of Groningen, the Netherlands (1992) and a MBA degree from Rotterdam School of Management (2011). He has over 25 years of experience in the Life Science sector and has a track record in business development, product development and GMP manufacturing.